文献速递消化系统肿瘤

立体定向体部放疗对比索拉非尼单药治疗肝细胞癌:NRG Oncology/RTOG 1112 3期随机临床试验

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项多中心3期随机临床试验将局部晚期肝细胞癌患者1:1随机分配至索拉非尼单药或立体定向体部放疗(SBRT)后序贯索拉非尼,主要终点为总生存期(OS)。索拉非尼组中位OS为12.3个月,SBRT联合索拉非尼组为15.8个月(HR 0.77,90% CI 0.59-1.01,单侧P=0.06),未达统计学显著;校正分层因素后OS改善(HR 0.72,95% CI 0.52-0.99,双侧P=0.04),中位无进展生存期(PFS)从5.5个月改善至9.2个月(HR 0.55,95% CI 0.40-0.75,双侧P<0.001)。

要点

  • 索拉非尼组中位OS 12.3个月 vs SBRT联合索拉非尼组15.8个月,HR 0.77,未达统计学显著。
  • 中位PFS索拉非尼组5.5个月 vs SBRT联合索拉非尼组9.2个月,HR 0.55,双侧P<0.001。
  • 治疗相关≥3级不良事件索拉非尼组42% vs SBRT联合索拉非尼组47%,P=0.52。

核心结论

  • 在局部晚期肝细胞癌患者中,与索拉非尼单药相比,SBRT联合索拉非尼与临床重要但未达统计学显著的总生存期改善相关。

研究设计与样本

  • 多中心3期随机临床试验,将肝细胞癌患者1:1随机分配至索拉非尼单药或SBRT后序贯索拉非尼,按体能状态、肝功能、转移程度和大血管侵犯分层。
  • 入组患者为不适合或对标准局部区域治疗难治、且适合一线系统治疗的肝细胞癌患者;数据收集自2013年4月至2021年3月,数据分析自2022年7月至2023年8月。
  • 共随机193例患者,177例符合纳入标准;因系统治疗标准治疗变化而提前终止入组。

主要发现

  • 截至2022年7月1日,索拉非尼组中位OS为12.3个月(90% CI 10.6-14.3),SBRT联合索拉非尼组为15.8个月(90% CI 11.4-19.2),HR 0.77(90% CI 0.59-1.01),单侧P=0.06。
  • 校正分层因素后,SBRT联合索拉非尼组OS改善,HR 0.72(95% CI 0.52-0.99),双侧P=0.04。
  • 中位PFS从索拉非尼组5.5个月(95% CI 3.4-6.3)改善至SBRT联合索拉非尼组9.2个月(95% CI 7.5-11.9),HR 0.55(95% CI 0.40-0.75),双侧P<0.001。
  • 治疗相关≥3级不良事件在索拉非尼组为37/88(42%),SBRT联合索拉非尼组为39/83(47%),P=0.52。
  • 治疗相关死亡索拉非尼组2例(死因未另行说明和肝衰竭),SBRT联合索拉非尼组1例(肺部感染)。

关键数值与推荐

  • SBRT剂量为27.5至50 Gy分5次照射。
  • 主要终点为总生存期(OS);次要终点为无进展生存期(PFS)、不良事件和生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因系统治疗标准治疗变化而提前终止入组。
  • 主要终点OS未达统计学显著(HR 0.77,90% CI 0.59-1.01,单侧P=0.06)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy. OBJECTIVE: To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone. DESIGN, SETTING, AND PARTICIPANTS: This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metastases, and macrovascular invasion. Eligible patients had HCC unsuitable for or refractory to standard local-regional therapies and were candidates for first-line systemic therapy. Data were collected from April 2013 to March 2021, and data were analyzed from July 2022 to August 2023. INTERVENTION: Personalized SBRT, 27.5 to 50 Gy in 5 fractions. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS), adverse events, and quality of life. RESULTS: Of 193 patients randomized, 177 were eligible. Accrual was stopped early due to a change in standard-of-care systemic therapy. Of 177 included patients, 150 (84.7%) were male, and the median (IQR) age was 66 (60-72) years. Macrovascular invasion was seen in 131 (74.0%). As of July 1, 2022, the median OS was 12.3 months (90% CI, 10.6-14.3) with sorafenib vs 15.8 months (90% CI, 11.4-19.2) following SBRT and sorafenib (hazard ratio [HR], 0.77; 90% CI, 0.59-1.01; 1-sided P = .06). Adjusting for stratification factors, OS was improved with SBRT (HR, 0.72; 95% CI, 0.52-0.99; 2-sided P = .04). Median PFS was improved from 5.5 months (95% CI, 3.4-6.3) with sorafenib to 9.2 months (95% CI, 7.5-11.9) with SBRT and sorafenib (HR, 0.55; 95% CI, 0.40-0.75; 2-sided P < .001). Treatment-related grade 3 or higher adverse events were seen in 37 of 88 (42%) and 39 of 83 (47%) of patients treated with sorafenib vs SBRT and sorafenib, respectively (P = .52). There were 2 treatment-related deaths in the sorafenib group (death not otherwise specified and liver failure) and 1 in the SBRT and sorafenib group (lung infection). At 6 months, improved quality of life was seen in 2 of 20 (10%) and 6 of 17 (35%) of patients treated with sorafenib and SBRT and sorafenib, respectively. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, among patients with locally advanced HCC, SBRT was associated with a clinically important but not statistically significant improved overall survival compared with sorafenib alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01730937.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dawson LA, Winter KA, Knox JJ, et al. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 39699905. doi:10.1001/jamaoncol.2024.5403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。